otl-101
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Nov 11, 2019 (NCT04140539)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Adenosine deaminaseSupplementation
ADA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04140539 | Phase 2/Phase 3 (Phase 3) | Nov 11, 2019 | Orchard Therapeutics Limited, University of California, Los Angeles |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Orchard Therapeutics Limited | For profit | 1 | 0 | 1 | 2019 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1